Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Butantan Quadrivalent Influenza Vaccine
NCT03927131Phase 3Completed
- Sponsor
- Instituto Butantan
- Start
- May 2021
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QIV-IB in influenza (6 arms), sponsored by Instituto Butantan. Primary endpoints: Number of Adverse Events at 42 days, Hemagglutinin Inhibition Geometric Mean Titer at 21 days and 1 more. Started May 2021; status: completed.
02
Drugs
QIV-IB
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03927131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927131.